Registry of Chinese adults with relapsed multiple myeloma treated with elranatamab
Observes how elranatamab works in Chinese adults with relapsed multiple myeloma.
Plain-language title generated from the registry record
Registry title: ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Peking University People's HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT07320326
- Record updated
- 6 January 2026
- Original description
This registry study will provide valuable evidence to assess and validate its effectiveness in the Chinese MM population, refine clinical application strategies, and support the optimization of BCMA BsAbs use in MM treatment in China.Read full original descriptionShow less
A Multi-center, Ambispective, Non-interventional, Observational, Registry Study of the Effectiveness of Elranatamab in Patients With Triple-class Exposed Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice in China(ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab)
This registry study will provide valuable evidence to assess and validate its effectiveness in the Chinese MM population, refine clinical application strategies, and support the optimization of BCMA BsAbs use in MM treatment in China.
Inclusion: Participants with TCE-RRMM who have received or are planning to start Elranatamab treatment according to the local Health Authority approved product label (routine-care); Patients must meet the following criteria to be eligible for inclusion in the study:; In the retrospective part:; Male or female patients above 18 years old; Patients diagnosed with RRMM(IMWG); Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory drug and anti-CD38 monoclonal antibody in any order during the course of treatment; Patients received at least 1 treatment dose of Elranatamab treatment after commercial launch in China and according to the approved product label (routine-care) in China (consistent with the approved label in China)*; Patients understand and voluntarily sign an ICF ; In the prospective part:; Male or female patients above 18 years old; Patients diagnosed with RRMM (IMWG); Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory drug and anti-CD38 monoclonal antibody in any order during the course of treatment; Patients treated with elranatamab as monotherapy or a part of combination therapy and according to the approved product label (routine-care) in China (consistent with the approved label in China)*; Patient understand and voluntarily sign an ICF. *Note: If patients received Elranatamab treatment at a Hong Kong site,the treatment must consist the indications approved in Hong Kong.
Exclusion: Patients with documented diagnosis of other cancers prior to the diagnosis of MM; Patients enrolled in interventional clinical trials of any drug for MM treatment; Patients with documented diagnosis of other cancers prior to the diagnosis of MM; Patients enrolled in interventional clinical trials of Elranatamab or any other drug for MM treatment; Patients with incomplete medical records or missing clinical laboratory data that preclude effectiveness evaluation; Patients meeting the following criteria will not be included in the study:; In the retrospective part:; Patients who, in the opinion of the investigator, have other factors that make them unsuitable for study participation; In the prospective part:; Patients with contraindication listed in the package insert of elranatamab.